130403-94-0

Basic information

• Product Name: (S)-3-Pyrrolidinol acetate (ester)
• Synonyms: (S)-3-Pyrrolidinol acetate (ester)
• CAS NO: 130403-94-0
• Molecular Weight: 129.159
• Mol File: 130403-94-0.mol

Chemical Properties

• CAS DataBase Reference: (S)-3-Pyrrolidinol acetate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-Pyrrolidinol acetate (ester)(130403-94-0)
• EPA Substance Registry System: (S)-3-Pyrrolidinol acetate (ester)(130403-94-0)

Safety Data

• Hazardous Substances Data: 130403-94-0(Hazardous Substances Data)

Upstream product

• 124445-27-8 (3S)-1-benzyl-3-acetatoxypyrrolidine 
• 130403-93-9 (S)-benzyl 3-acetoxypyrrolidine-1-carboxylate 

Relevant articles and documents

PROTEIN KINASE INHIBITOR PRODRUGS

The present invention relates to ester and phosphate prodrugs of the protein kinase inhibitor N-(2-chloro-6-methylphenyl)-2-[[2-methyl-6-((S)-3-hydroxypyrrolidin-1- yl)pyrimidin4-yl]amino]thiazole-5-carboxarnide (compound X), stereoisomers, isomeric mixtures including racemic mixtures, and/or 4-deutero substituted derivatives thereof.

PYRIDONE DERIVATIVE

The invention provides pyridone derivatives represented by a general formula (I) [in the formula, R 1 and R 2 may be same or different and stands for H, etc., or R 1 and R 2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X 1 -X 3 may be same or different and stand for methine or N, provided not all of them simultaneously stand for nitrogen; X 4 -X 7 may be same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y 1 and Y 3 may be same or different and stand for single bond, -0-, -NR-, -S-, etc ; Y 2 stands for lower lkylene, etc.; R stands for H, etc., L stands for methylene; Z 1 and Z 2 may be same or different and stand for single bond or lower alkylene; or R 1 , L and Z 2 may form an aliphatic nitrogen-containing heterocyclic group with the N to which R 1 binds; and Ar stands for aromatic carbocyclic group, etc.].

3- or 4-substituted oxotremorine derivatives

This disclosure describes novel 3 or 4 substituted oxotremorine derivatives having polar substituted oxygen or sulfur groups. The compounds have cholinergic activity. Also disclosed are methods for treating diseases of the central nervous system in mammals employing the compounds, pharmaceutical preparations containing the compounds and processes for the production of the compounds.